| Literature DB >> 26909718 |
Carl Diedrich Schlenkhoff1, Eberhard Knüpfer, Markus Essler, Hojjat Ahmadzadehfar.
Abstract
An 80-year-old patient with castrate-resistant prostate cancer presented to our department for PSMA imaging because of a rising prostate-specific antigen (PSA) level. The tumor was diagnosed in 2004. GnRh analog was the only treatment the patient received. Two cycles of Lu-PSMA-617 were performed with a 2-month interval in between. Ten months after finishing with 2 cycles of Lu-PSMA therapy, we noticed a continuous falling PSA level and a decreasing tumor spread in the PET/CT imaging just under the hormone therapy.Entities:
Mesh：
Substances：
Year: 2016 PMID： 26909718 DOI： 10.1097/RLU.0000000000001200
Source DB: PubMed Journal: Clin Nucl Med ISSN： 0363-9762 Impact factor: 7.794